<p>Rhenman  Partners Asset Management AB 在最近向证券交易委员会提交的 13F 表格中披露，其在 LivaNova PLC (NASDAQ:LIVN - 免费报告) 的持股在第四季度增加了 258.5%。该机构投资者在此期间额外购买了 137,000 股后，持有该公司 190,000 股股票。根据其最近向证券交易委员会的提交，Rhenman  Partners Asset Management AB 持有的 LivaNova 股票约占 0.35%，价值 11,691,000 美元。</p>
<p>其他几家机构投资者和对冲基金最近也对其在 LIVN 的持仓进行了调整。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 LivaNova 的持仓增加了 4.0%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前持有 35,497 股该公司的股票，价值 1,394,000 美元，此前在上个季度额外购买了 1,360 股。高盛集团在第一季度将其在 LivaNova 的持仓增加了 4.6%。高盛集团目前持有 814,974 股该公司的股票，价值 32,012,000 美元，此前在上个季度额外购买了 36,094 股。瑞银资产管理美国有限公司的一个独立业务单位在第一季度将其在 LivaNova 的持仓增加了 10.0%。瑞银资产管理美国有限公司的这个独立业务单位目前持有 168,863 股该公司的股票，价值 6,633,000 美元，此前在上个季度额外购买了 15,405 股。Intech Investment Management LLC 在第一季度将其在 LivaNova 的持仓增加了 19.6%。Intech Investment Management LLC 目前持有 43,879 股该公司的股票，价值 1,724,000 美元，此前在上个季度额外购买了 7,195 股。最后，Strs Ohio 在第一季度购买了 LivaNova 的新股份，价值约 130,000 美元。机构投资者持有该公司 97.64% 的股票。</p>
<h2>内部买卖</h2>
<p>在其他 LivaNova 的新闻中，董事 Francesco Bianchi 于 5 月 26 日星期二出售了 1,800 股 LivaNova 股票。该股票以平均价格 75.75 美元出售，总价值为 136,350.00 美元。出售完成后，该董事持有 7,228 股该公司的股票，价值约 547,521 美元。此次交易使其持仓减少了 19.94%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有该公司 0.35% 的股票。</p>
<h2>LivaNova 股价下跌 0.7%</h2>
<p>NASDAQ:LIVN 周五开盘价为 79.39 美元。该公司的流动比率为 1.33，速动比率为 1.11，债务与股本比率为 0.24。LivaNova PLC 的 12 个月低点为 41.01 美元，12 个月高点为 80.74 美元。该公司的市值为 43.6 亿美元，市盈率为 40.71，贝塔值为 0.88。该公司的 50 日简单移动平均为 69.08 美元，200 日简单移动平均为 65.77 美元。</p>
<p>LivaNova (NASDAQ:LIVN - 获取免费报告) 最近于 5 月 6 日星期三发布了其财报。该公司报告本季度每股收益为 0.98 美元，超出分析师一致预期的 0.85 美元，超出幅度为 0.13 美元。LivaNova 的净利润率为 7.48%，股本回报率为 16.48%。该业务在本季度的收入为 3.6226 亿美元，而一致预期为 3.4605 亿美元。在去年同期，该公司发布的每股收益为 0.88 美元。该公司的收入同比增长 14.3%。LivaNova 已将其 2026 财年的指引设定为每股收益 4.200-4.300 美元。研究分析师预测 LivaNova PLC 本年度每股收益将达到 3.72 美元。</p>
<h2>华尔街分析师观点</h2>
<p>几位股票研究分析师最近对该股票发表了看法。Needham  Company LLC 在 2 月 25 日的研究报告中将 LivaNova 的目标价从 64.00 美元上调至 81.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 在 5 月 7 日的研究报告中将 LivaNova 的目标价从 78.00 美元下调至 76.00 美元，并为该公司设定了 “跑赢大盘” 评级。Stifel Nicolaus 在 2 月 25 日的研究报告中为 LivaNova 设定了 80.00 美元的目标价。Barclays 在 5 月 7 日的研究报告中将 LivaNova 的目标价从 73.00 美元上调至 76.00 美元，并给予该股票 “持平” 评级。最后，Weiss Ratings 在 5 月 7 日的研究报告中将 LivaNova 的评级从 “卖出 (d+)” 上调至 “持有 (c)”。六位股票研究分析师对该股票给予了买入评级，三位分析师对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 79.38 美元。</p>
<p><strong>查看我们对 LivaNova 的最新分析</strong></p>
<h2>关于 LivaNova</h2>
<p>(免费报告)</p>
<p>LivaNova plc 是一家全球医疗技术公司，开发和制造心脏外科和神经调节市场的产品和疗法。公司总部位于英国伦敦和美国德克萨斯州休斯顿，LivaNova 为超过 100 个国家的医院、诊所和医疗服务提供者提供服务。该公司的主要关注点是通过心肺旁路、心脏保护、循环支持和神经刺激疗法的创新来改善患者护理。</p>
<p>心脏外科业务部门提供一系列用于心肺旁路手术的产品，包括氧合器、心肺机、动脉过滤器、导管和无缝心脏瓣膜。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们更看好的股票，胜过 LivaNova</li>
<li>SpaceX 敲响钟声，打破所有记录</li>
<li>Adobe 股票刚刚变得更便宜——华尔街是否忽视了这个故事？</li>
<li>3 只股息股票低于 50 美元，支付你以应对通货膨胀</li>
<li>127 吉瓦问题：为什么 AI 需要自己的电力</li>
</ul>
<p><strong>想知道其他对 LIVN 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 LivaNova PLC (NASDAQ:LIVN - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 LivaNova 吗？</h2>
<p>在考虑 LivaNova 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 LivaNova 并不在名单上。</p>
<p>虽然 LivaNova 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LIVN

瑞银集团

高盛

<p>Rhenman & Partners Asset Management AB 在第四季度将其在 LivaNova PLC 的持股增加了 258.5%，收购了 137,000 股，总持股达到 190,000 股，价值 1169 万美元。其他机构如高盛和瑞银集团也增加了持仓。与此同时，董事 Francesco Bianchi 卖出了 1,800 股。LivaNova 最近报告了强劲的财报，收益超出预期，每股收益为 0.98 美元，营收为 3.6226 亿美元。分析师们已调整了目标股价，Needham 将其目标价上调至 81 美元</p>

<p>Rhenman &amp; Partners Asset Management AB lifted its position in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 258.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 190,000 shares of the company's stock after acquiring an additional 137,000 shares during the period. Rhenman &amp; Partners Asset Management AB owned approximately 0.35% of LivaNova worth $11,691,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p>
<div class="lb-trans"><p>Rhenman  Partners Asset Management AB 在最近向证券交易委员会提交的 13F 表格中披露，其在 LivaNova PLC (NASDAQ:LIVN - 免费报告) 的持股在第四季度增加了 258.5%。该机构投资者在此期间额外购买了 137,000 股后，持有该公司 190,000 股股票。根据其最近向证券交易委员会的提交，Rhenman  Partners Asset Management AB 持有的 LivaNova 股票约占 0.35%，价值 11,691,000 美元。</p>
</div><p>Several other institutional investors and hedge funds also recently made changes to their positions in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company's stock valued at $1,394,000 after acquiring an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of LivaNova by 4.6% during the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company's stock valued at $32,012,000 after acquiring an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of LivaNova by 10.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company's stock valued at $6,633,000 after acquiring an additional 15,405 shares in the last quarter. Intech Investment Management LLC increased its position in shares of LivaNova by 19.6% during the first quarter. Intech Investment Management LLC now owns 43,879 shares of the company's stock valued at $1,724,000 after acquiring an additional 7,195 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of LivaNova during the first quarter valued at approximately $130,000. Institutional investors own 97.64% of the company's stock.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也对其在 LIVN 的持仓进行了调整。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第一季度将其在 LivaNova 的持仓增加了 4.0%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前持有 35,497 股该公司的股票，价值 1,394,000 美元，此前在上个季度额外购买了 1,360 股。高盛集团在第一季度将其在 LivaNova 的持仓增加了 4.6%。高盛集团目前持有 814,974 股该公司的股票，价值 32,012,000 美元，此前在上个季度额外购买了 36,094 股。瑞银资产管理美国有限公司的一个独立业务单位在第一季度将其在 LivaNova 的持仓增加了 10.0%。瑞银资产管理美国有限公司的这个独立业务单位目前持有 168,863 股该公司的股票，价值 6,633,000 美元，此前在上个季度额外购买了 15,405 股。Intech Investment Management LLC 在第一季度将其在 LivaNova 的持仓增加了 19.6%。Intech Investment Management LLC 目前持有 43,879 股该公司的股票，价值 1,724,000 美元，此前在上个季度额外购买了 7,195 股。最后，Strs Ohio 在第一季度购买了 LivaNova 的新股份，价值约 130,000 美元。机构投资者持有该公司 97.64% 的股票。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><p>In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total value of $136,350.00. Following the completion of the sale, the director owned 7,228 shares of the company's stock, valued at approximately $547,521. The trade was a 19.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.35% of the company's stock.</p>
<div class="lb-trans"><p>在其他 LivaNova 的新闻中，董事 Francesco Bianchi 于 5 月 26 日星期二出售了 1,800 股 LivaNova 股票。该股票以平均价格 75.75 美元出售，总价值为 136,350.00 美元。出售完成后，该董事持有 7,228 股该公司的股票，价值约 547,521 美元。此次交易使其持仓减少了 19.94%。该交易已在向 SEC 提交的文件中披露，可以通过此超链接访问。公司内部人士持有该公司 0.35% 的股票。</p>
</div><h2>LivaNova Trading Down 0.7%</h2>
<div class="lb-trans"><h2>LivaNova 股价下跌 0.7%</h2>
</div><p>NASDAQ:LIVN opened at $79.39 on Friday. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. LivaNova PLC has a 12 month low of $41.01 and a 12 month high of $80.74. The company has a market cap of $4.36 billion, a PE ratio of 40.71 and a beta of 0.88. The company has a 50 day simple moving average of $69.08 and a two-hundred day simple moving average of $65.77.</p>
<div class="lb-trans"><p>NASDAQ:LIVN 周五开盘价为 79.39 美元。该公司的流动比率为 1.33，速动比率为 1.11，债务与股本比率为 0.24。LivaNova PLC 的 12 个月低点为 41.01 美元，12 个月高点为 80.74 美元。该公司的市值为 43.6 亿美元，市盈率为 40.71，贝塔值为 0.88。该公司的 50 日简单移动平均为 69.08 美元，200 日简单移动平均为 65.77 美元。</p>
</div><p>LivaNova (NASDAQ:LIVN - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The business had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the previous year, the firm posted $0.88 EPS. The firm's revenue was up 14.3% on a year-over-year basis. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. Research analysts forecast that LivaNova PLC will post 3.72 earnings per share for the current year.</p>
<div class="lb-trans"><p>LivaNova (NASDAQ:LIVN - 获取免费报告) 最近于 5 月 6 日星期三发布了其财报。该公司报告本季度每股收益为 0.98 美元，超出分析师一致预期的 0.85 美元，超出幅度为 0.13 美元。LivaNova 的净利润率为 7.48%，股本回报率为 16.48%。该业务在本季度的收入为 3.6226 亿美元，而一致预期为 3.4605 亿美元。在去年同期，该公司发布的每股收益为 0.88 美元。该公司的收入同比增长 14.3%。LivaNova 已将其 2026 财年的指引设定为每股收益 4.200-4.300 美元。研究分析师预测 LivaNova PLC 本年度每股收益将达到 3.72 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>Several equities research analysts recently weighed in on the stock. Needham &amp; Company LLC raised their price target on shares of LivaNova from $64.00 to $81.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, February 25th. Robert W. Baird reduced their price target on shares of LivaNova from $78.00 to $76.00 and set an &#34;outperform&#34; rating for the company in a research report on Thursday, May 7th. Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a research report on Wednesday, February 25th. Barclays lifted their target price on shares of LivaNova from $73.00 to $76.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Thursday, May 7th. Finally, Weiss Ratings raised shares of LivaNova from a &#34;sell (d+)&#34; rating to a &#34;hold (c)&#34; rating in a research report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $79.38.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该股票发表了看法。Needham  Company LLC 在 2 月 25 日的研究报告中将 LivaNova 的目标价从 64.00 美元上调至 81.00 美元，并给予该公司 “买入” 评级。Robert W. Baird 在 5 月 7 日的研究报告中将 LivaNova 的目标价从 78.00 美元下调至 76.00 美元，并为该公司设定了 “跑赢大盘” 评级。Stifel Nicolaus 在 2 月 25 日的研究报告中为 LivaNova 设定了 80.00 美元的目标价。Barclays 在 5 月 7 日的研究报告中将 LivaNova 的目标价从 73.00 美元上调至 76.00 美元，并给予该股票 “持平” 评级。最后，Weiss Ratings 在 5 月 7 日的研究报告中将 LivaNova 的评级从 “卖出 (d+)” 上调至 “持有 (c)”。六位股票研究分析师对该股票给予了买入评级，三位分析师对该公司的股票给予了持有评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 79.38 美元。</p>
</div><p><strong>View Our Latest Analysis on LivaNova</strong></p>
<div class="lb-trans"><p><strong>查看我们对 LivaNova 的最新分析</strong></p>
</div><h2>About LivaNova</h2>
<div class="lb-trans"><h2>关于 LivaNova</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company's primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.</p>
<div class="lb-trans"><p>LivaNova plc 是一家全球医疗技术公司，开发和制造心脏外科和神经调节市场的产品和疗法。公司总部位于英国伦敦和美国德克萨斯州休斯顿，LivaNova 为超过 100 个国家的医院、诊所和医疗服务提供者提供服务。该公司的主要关注点是通过心肺旁路、心脏保护、循环支持和神经刺激疗法的创新来改善患者护理。</p>
</div><p>The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.</p>
<div class="lb-trans"><p>心脏外科业务部门提供一系列用于心肺旁路手术的产品，包括氧合器、心肺机、动脉过滤器、导管和无缝心脏瓣膜。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than LivaNova</li>
<li>SpaceX Rings the Bell and Shatters Every Record</li>
<li>Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?</li>
<li>3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation</li>
<li>The 127-Gigawatt Problem: Why AI Needs Its Own Power</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 LivaNova</li>
<li>SpaceX 敲响钟声，打破所有记录</li>
<li>Adobe 股票刚刚变得更便宜——华尔街是否忽视了这个故事？</li>
<li>3 只股息股票低于 50 美元，支付你以应对通货膨胀</li>
<li>127 吉瓦问题：为什么 AI 需要自己的电力</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LIVN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LIVN 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 LivaNova PLC (NASDAQ:LIVN - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TElWTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=LIVN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in LivaNova Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 LivaNova 吗？</h2>
</div><p>Before you consider LivaNova, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 LivaNova 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 LivaNova 并不在名单上。</p>
</div><p>While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 LivaNova 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rhenman & Partners Asset Management AB Purchases 137,000 Shares of LivaNova PLC $LIVN

Market Beat

LivaNova

Stifel Financial

巴克莱银行

GS Hldg R

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Rhenman & Partners 资产管理公司购入了 LivaNova PLC 的 137,000 股股票 $LIVN